Welcome to our dedicated page for PepGen news (Ticker: PEPG), a resource for investors and traders seeking the latest updates and insights on PepGen stock.
PepGen Inc. (Nasdaq: PEPG) is a clinical-stage biotechnology company developing next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases. News about PEPG often centers on progress with its Enhanced Delivery Oligonucleotide (EDO) platform and its lead investigational candidate, PGN-EDODM1, in myotonic dystrophy type 1 (DM1).
Investors following PepGen’s news can expect updates on clinical trial milestones from the FREEDOM-DM1 Phase 1 single ascending dose study and the FREEDOM2-DM1 Phase 2 multiple ascending dose trial, including reported splicing correction data, safety observations, and study enrollment status. The company has highlighted results such as mean splicing correction in DM1 patients and described PGN-EDODM1 as generally well tolerated at evaluated doses in its communications.
PepGen’s news flow also includes corporate and financing announcements, such as underwritten public offerings of common stock under a shelf registration statement on Form S-3, with stated use of proceeds to fund the FREEDOM-DM1 and FREEDOM2-DM1 trials and general corporate purposes. Regulatory and intellectual property developments, including the issuance of a U.S. composition of matter patent for PGN-EDODM1 and FDA Orphan Drug and Fast Track designations for DM1, are additional themes in the company’s press releases.
Other PEPG news items feature executive and governance updates, such as the appointment of a Chief Business and Legal Officer and option repricing actions under the company’s equity plans, as well as participation in investor and scientific conferences where PepGen’s data are presented. For readers tracking PEPG stock, this news page provides a centralized view of clinical, regulatory, financial, and corporate developments that shape the company’s clinical-stage pipeline and capital strategy.
PepGen Inc. (Nasdaq: PEPG), a biotechnology company focused on oligonucleotide therapies, announced its participation in the 2023 American Academy of Neurology Annual Meeting from April 22-27 in Boston. The company will feature two oral and two poster presentations, highlighting advancements in treatments for Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD). Ashling Holland, Ph.D., will present preclinical data for DM1 on April 27, while two presentations on DMD will occur on April 23, showcasing results from a Phase 1 study of PGN-EDO51 and a study design for PGN-EDODM1. PepGen aims to revolutionize the treatment landscape for severe neuromuscular diseases through its Enhanced Delivery Oligonucleotide platform, demonstrating a commitment to addressing these critical health challenges.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, Ph.D., will present at the 22nd Annual Needham Virtual Healthcare Conference on April 20th, 2023, at 8:00 AM EDT. The presentation will be available for live streaming and will also be archived for one year on the company’s website. PepGen focuses on advancing next-generation oligonucleotide therapies aimed at severe neuromuscular and neurological diseases, utilizing its Enhanced Delivery Oligonucleotide (EDO) platform. This platform leverages over a decade of research to enhance the uptake and efficacy of oligonucleotide therapeutics through cell-penetrating peptides.
PepGen Inc. (Nasdaq: PEPG) reported its financial results for Q4 and full year 2022, highlighting significant advancements in its clinical pipeline. The company generated first-in-human data for PGN-EDO51, targeting Duchenne muscular dystrophy (DMD), and plans to initiate Phase 2 studies in 2023. Financially, PepGen reported a net loss of $69.1 million for 2022, an increase from $27.3 million in 2021. R&D expenses rose to $54.1 million, reflecting heightened clinical activities. The company has $181.8 million in cash, funding operations into early 2025. Overall, PepGen aims to develop transformative therapies for severe neuromuscular diseases.
PepGen Inc. (Nasdaq: PEPG) has presented promising clinical and nonclinical data for its Enhanced Oligonucleotide Delivery (EDO) platform at the MDA Conference in Dallas. The data highlights PGN-EDO51's ability to achieve a 34.9% exon skipping in non-human primates after four monthly doses, significantly higher than the 2.5% observed after a single dose. PepGen plans to initiate the CONNECT1-EDO51 Phase 2 study in DMD patients in the first half of 2023, with results expected in 2024. Additionally, the company aims to start the FREEDOM-DM1 Phase 1 study for myotonic dystrophy type 1 (DM1) patients in 2023, targeting safety and efficacy.
PepGen Inc. (Nasdaq: PEPG), a biotechnology company focused on oligonucleotide therapies, announced that its President and CEO, James McArthur, Ph.D., will present at Stifel’s CNS Days Conference on March 28, 2023, at 1:30 PM EST. The event aims to showcase PepGen's innovative approach to treating severe neuromuscular and neurological diseases through its Enhanced Delivery Oligonucleotide (EDO) platform, which leverages cell-penetrating peptides. A live webcast of the presentation will be available, with an archive for one year on PepGen's Investor Relations website.
PepGen Inc. (Nasdaq: PEPG) is set to report its fourth quarter and full year 2022 financial results on March 23, 2023. The clinical-stage biotechnology company focuses on advancing oligonucleotide therapies to treat severe neuromuscular and neurological diseases. PepGen's management will also host a conference call and audio webcast at 4:30 PM ET to discuss these results. The company employs an Enhanced Delivery Oligonucleotide (EDO) platform, leveraging cell-penetrating peptides to enhance therapeutic uptake and effectiveness. A replay of the event will be archived for one year.
PepGen Inc. (Nasdaq: PEPG) announced its participation in the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference from March 19-22, 2023, in Dallas, Texas. The company plans to present data on PGN EDO51 for Duchenne Muscular Dystrophy and PGN-EDODM1 for Myotonic Dystrophy Type 1, with presentations scheduled for March 22. Notably, PepGen will release a press statement after its presentations and provide access to the poster and data presentations on its Investor Relations website. The company's Enhanced Delivery Oligonucleotide platform aims to advance treatments for severe neuromuscular and neurological diseases.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, Ph.D., will present at the SVB Securities’ Global Biopharma Virtual Conference on February 16, 2023, at 10:40 A.M. EST. The presentation aims to highlight PepGen's next-generation oligonucleotide therapies designed to transform treatment for severe neuromuscular and neurological diseases.
The event will be available for live streaming, and a replay will be accessible on PepGen's website for 90 days afterward. The company focuses on enhancing the delivery of oligonucleotide therapeutics through its Enhanced Delivery Oligonucleotide (EDO) platform.
PepGen Inc. has announced positive preclinical results for PGN-EDODM1, a treatment for myotonic dystrophy type 1 (DM1). The product candidate, which uses Enhanced Delivery Oligonucleotide technology, has demonstrated a well-tolerated safety profile in studies with no off-target effects. Notably, it does not degrade DMPK transcripts, an important safety consideration. PepGen plans to initiate a single ascending dose clinical trial in DM1 patients in the first half of 2023. This marks a significant step forward as there are currently no approved therapies for DM1.
PepGen Inc. (NASDAQ: PEPG) announced promising exon skipping results from its product candidates PGN-EDO53, PGN-EDO45, and PGN-EDO44 for Duchenne muscular dystrophy (DMD). In non-human primates (NHPs), PGN-EDO53 achieved exon skipping levels of 36.4% after one dose and 57.2% after three doses, significantly outperforming the comparator PPMO molecule. Additionally, PGN-EDO45 and PGN-EDO44 demonstrated high exon skipping in human myoblasts, indicating potential for treating approximately 50% of DMD patients amenable to exon skipping. The results affirm PepGen's Enhanced Delivery Oligonucleotide platform's transformative potential.